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This case is about a 6-year-old boy with cystic ﬁbrosis (CF), suffering from allergic bronchopulmonary
aspergillosis (ABPA) with total atelectasis of the left lung. To prove the hypothesis that IgE mediated
disease is the major pathomechanism of ABPA, a bronchial provocation with Aspergillus fumigatus was
performed before and after treatment with omalizumab (OMA). We could demonstrate for the ﬁrst time
that OMA completely suppresses the early allergic reaction (EAR) after bronchial allergen challenge with
Aspergillus. Moreover, as has been shown by others, our patient showed a marked improvement of FEV1
without a relapse after tapering systemic steroid treatment.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a disease
primarily occurring in patients with asthma (1–2%) and cystic
ﬁbrosis (5–15%). This disease is characterized by a variety of clinical
signs (asthma related events, pulmonary inﬁltrates and bronchi-
ectasis) and immunologic responses to antigens of Aspergillus.
Diagnosis is often difﬁcult and classical diagnostic criteria include:
asthma, immediate cutaneous reactivity to Aspergillus, elevated
total IgE, and elevated speciﬁc IgE and IgG in response to Asper-
gillus, which may colonize the bronchial trees of patients. Standard
therapy targets the eradication of Aspergillus with antimycotics,
preferentially itraconazole, and the suppression of Aspergillus-
mediated inﬂammation by corticosteroids.1 However, relapses
often occur and many patients develop severe side-effects caused
by systemic steroid therapy.2
The underlying pathological mechanism of ABPA is not fully
understood. In particular the role of speciﬁc IgE in ABPA is unclear.
Some authors propose IgE is an innocent bystander whereas others
describe it as themajor cause of Th-2 driven disease. Indeed there is
increasing evidence that OMA, a recombinant humanized mono-
clonal antibody (mAb) that binds and neutralizes IgE is effective
and may be a corticosteroid sparing treatment in ABPA.3–5 In
keeping with our case we hypothesize that speciﬁc IgE plays
a major role in ABPA.ax: þ49 69 6310 6061.
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We report on a 6-year-old boy with CF who suffered from an
acute exacerbation and was found to have atelectasis of the left
lung in August 2008 as shown in Fig. 1. Bronchoscopy with bron-
choalveolar lavage revealed Aspergillus in culture. His total IgE
(1066 U/ml), speciﬁc IgE Aspergillus (29.7 U/ml), and eosinophils
(2175/ml) weremarkedly elevated. ABPAwas diagnosed and the boy
was treated with prednisone (1 mg/kg body weight/day) and itra-
conazole (8 mg/kg body weight/day) for four weeks as recom-
mended. He gradually improved and prednisone was tapered to
5 mg/daily in September 2008. At that time total IgE was 441 U/ml,
speciﬁc IgE against Aspergillus unchanged, and eosinophils 260/ml.
Bronchial methacholine challenge using a short protocol as
described,6 demonstrated severe hyperreactivity and gave further
evidence of the asthma-like picture which is often found in ABPA.7
To prove the concept that an IgE mediated mechanism is the
major cause of ABPA, we performed a titrated allergen provocation
test using the APS dosimeter technique (Cardinal Health) as
described previously.8 The doses of inhaled Aspergillus allergen
were increased according to the following pattern from step 1 to 6:
5, 10, 20, 40, 80, and 160 standardized biological units (SBU, Aller-
gopharma, Rhinebeck, Germany). Thus, the entire protocol deliv-
ered cumulative doses of 5, 15, 35, 75, 155, and 315 SBU. FEV1 was
measured 10 min after each step-up. All lung function tests were
performed according to the American Thoracic Society guidelines.9
Inhalationwas stopped if FEV1 dropped>20% compared to baseline
values. The allergen dose causing a 20% drop of FEV1 (PD20FEV1)
was calculated by logarithmic interpolation using an integrated
programme. As shown in Fig. 2 the patient developed a signiﬁcant
EAR at a PD20FEV1 of 220 SBU. No late asthmatic reaction occurred
Fig. 1. Total atelectasis of left lung at presentation.
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every four weeks. Since OMA has been previously reported to
reduce LAR within two weeks and EAR within four weeks,10 the
allergen provocation test was repeated after four weeks of treat-
ment with OMA. No EAR was demonstrated at cumulative provo-
cation dosing up to 315 SBU (Fig. 2). During the next six months the
patient had improvement of lung function and showed no relapse
under treatment with OMA and itraconazole. However, during
colds mild virus induced wheezing was present with a transient
drop of FEV1, indicating high airway hyperreactivity.3. Discussion
The underlying pathological mechanism of ABPA is not fully
understood. ABPA may develop in genetically susceptible CF
patients due to HLA-DR2 and DR5 restriction, increased sensitivity
to IL-4 stimulation, and increased Aspergillus allergen-speciﬁc Th-2
CD4þ T-cell-mediated responses.1 The importance of a Th-2
mediated immune response was recently highlighted by the
ﬁnding of increased levels of the Th-2 cytokine TARC (ThymusFig. 2. Bronchial allergen provocation before (-) and after (C) treatment with
omalizumab. Squared line: fall of FEV1 at a PD20 of 220 SBU Aspergillus. Dotted line:
course of FEV1 after a cumulative dose of 315 SBU Aspergillus.activation regulated chemokine).11 Interestingly the level of TRAC
in patients with CF correlates positively with speciﬁc IgE to Asper-
gillus fumigatus.11 In addition, Aspergillus proteases play a role in
facilitation of antigen transport via chitinases by damaging the
epithelial integrity and by a direct interaction with epithelial cell
surface receptors, resulting in pro-inﬂammatory cytokine produc-
tion and corresponding inﬂammatory responses.1
The role of IgE and mast cell activation is a matter of debate.
High total and speciﬁc IgE levels, an asthma-like picture and
increased airway hyperreactivity are highly suggestive that in the
beginning ABPA is just an IgE mediated disease. We have demon-
strated for the ﬁrst time that OMA completely suppresses the EAR
after bronchial allergen provocation with Aspergillus. Moreover, as
has been shown by others, our patient showed a marked
improvement of FEV1 without a relapse after stopping systemic
steroid treatment.3–5
In children treatment of allergic patients with OMA is limited to
IgE levels from 30 to 1300 kU/L. Efﬁcacy of OMA to neutralize high
IgE levels>1300 kU/L is unclear.12 Recently there was a preliminary
report that OMA was effective in patients with asthma and high
IgE.13 In addition we have demonstrated the efﬁcacy and safety of
OMA in attenuating allergen-induced bronchoconstriction in
patients with allergic asthma and pre-treatment IgE levels up to
2000 U/ml.14 Since ABPA patients usually have high levels of IgE, an
alternative therapeutic option could be the reduction of the total
and speciﬁc IgE by systemic steroids to a treatable level.
In conclusion our case suggests that IgE mediated disease is the
major mechanistic pathway of ABPA, and OMA has potential to
control ABPA.
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